546 / 1631
PRIMA Study – Rituximab maintenance
Salles, G. et al. J Clin Oncol 28:15s, 2010
(N=1200)
Dealer’s Choice
•Untreated
•Follicular NHL
•Grade 1-3a
•High tumor
burden
CHOP x 6
CVP x 8
FCM x 6
Rituximab x 8
PR
CR
Rituximab x 8
Rituximab x 8
R
Rituximab q2
months x 2 years
Observation
Eligibility
Primary end point: PFS
(45% improvement in median PFS after randomization)